The new code is expected to streamline the reimbursement process and positively impact the way remittances are received from Medicare and commercial payors.
The company attributed increases to both its revenues and expenses to the 2014 acquisition of RedPath Integrated Pathology and two tests from Asuragen.
In November, the company said it was selling off its biomedical commercialization and marketing services business in order to focus on its diagnostic offerings.
The test is used in conjunction with the firm's ThyGenX oncogene panel to assess fine needle aspiration samples from indeterminate thyroid nodules.
The firm performed a long-term, prospective study and noted that the test improved outcomes for patients and helped doctors monitor patients with benign disease.
PDI said that the workforce reduction would save $400,000 in December, and shave $1.9 million off of its annual operating costs going forward.
PDI also said that it would assume the name of its subsidiary, Interpace Diagnostics, to better reflect its focus on its molecular diagnostic operations.
The International Thyroid Congress and Annual Meeting of the American Thyroid Association announced studies validating diagnostics tests for several companies.
The medical policy update makes the unnamed insurer the first commercial plan to cover ThyraMIR, a microRNA gene expression classifier launched earlier this year.
Aetna is the first major commercial insurer to cover Interpace's ThyGenX and brings the total number of covered lives for it to more than 100 million.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.